VELCADE,Rituximab,Cyclophosphamide and Decadron

Part of paid clinical trials in Niles, Illinois.

Sponsor
Oncology Specialists, S.C.
Study ID
NCT00413959
Phase
PHASE2
Status
Terminated

Conditions

  • Lymphoma, B-Cell
  • Lymphoma, Non-Hodgkin

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • VELCADE® — DRUG
    1.6 mg/m\^2 of Velcade® given intravenously on days 1, 8, 15 and 22.
  • Rituximab — DRUG
    375 mg/m\^2 of Rituximab given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
  • Cyclophosphamide — DRUG
    400 mg/m\^2 of Cyclophosphamide given orally on days 1-4 of each cycle.
  • Decadron — DRUG
    40 mg given orally on days 1, 2, 8, 9, 15, 16, 22 and 23

Study Details

Overall response rate and Time to disease progression using this regimen in patients with low-grade B-Cell Non-Hodgkin's Lymphoma.

Key Dates

Start date
Aug 31, 2006
Status verified
Aug 2018
Primary completion
Jan 31, 2011
Completion
Jan 31, 2011

Study Design

Enrollment
12 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Velcade, Rituximab,Cyclophosphamide & Decadron
    Velcade 375 mg/m\^2 given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.

Primary Outcome Measure

Overall Response Rate Using This Regimen in Patients With Low-grade B-Cell Non-Hodgkin's Lymphoma. [ Time Frame: 4 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
Onocology Specialists, S.CNilesIllinois60714-
Oncology Specialists, S.CPark RidgeIllinois60068-

Find similar trials in Niles, IL

By research site
Onocology Specialists, S.C· Niles, ILOncology Specialists, S.C· Park Ridge, IL

Related Studies